What is the Historical Analysis of the Renal Biomarkers Market Size?
The renal biomarkers market has seen considerable growth due to a variety of factors.
• The renal biomarkers sector has experienced significant expansion in the past few years. The market size is forecasted to escalate from $1.28 billion in 2024 to a higher figure of $1.38 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.8%.
Factors attributed to this surge during the historical timeframe include the rising incidence of kidney-related illnesses, advancements in medical diagnostic technology, an aging global population, enhanced understanding and implementation of early disease detection, utilization of point-of-care testing, and an uptick in chronic diseases.
What is the Forecasted Growth of the Renal Biomarkers Market Size?
The renal biomarkers market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of renal biomarkers is predicted to witness substantial growth in the coming years, expanding to a value of $1.91 billion by 2029 at an 8.5% Compound Annual Growth Rate (CAGR).
This projected growth during the forecasted period can be attributed to factors such as the adoption of personalized and targeted therapies, the inclusion of biomarker testing in regular clinical procedures, rising markets in Asia and Latin America, non-invasive biomarker testing methods, and continual monitoring through wearable devices. Key trends observed during the forecast period encompass multiplex biomarker panels for in-depth disease profiling, application of AI and machine learning in biomarker discovery, reliance on biomarker-based companion diagnostics, point of care (POC) biomarker testing within home healthcare environments, and the use of biomarkers for early disease detection and prevention.
What Key Factors and Trends are Driving the Growth of the Renal Biomarkers Market?
The increasing number of elderly and young renal patients is likely to boost the growth of the renal biomarkers market. Elderly renal patients are typically those over the age of 70 suffering from advanced chronic kidney disease (CKD). Meanwhile, young renal patients are those diagnosed with renal disorders during childhood and early adult years. Renal biomarkers are utilised to assess the extent of kidney damage in these two patient groups. For example, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in June 2024 that mortality rates due to chronic kidney disease (CKD) saw an increase of 4.2% in 2021 and 6.2% in 2022. Consequently, the surge in the number of elderly and young renal patients is contributing to the expansion of the renal biomarkers market.
What are the Market Segments in the Renal Biomarkers Market?
The renal biomarkers market covered in this report is segmented –
1) By Biomarker Type: Functional Biomarker, Up Regulated Protein, Other Biomarker Types
2) By Diagnostic Technique: Enzyme-Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LS-MS)
3) By Application: Diagnosis And Disease Progression Monitoring, Research Homecare
4) By End User: Hospitals, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Functional Biomarker: Creatinine, Urea, Cystatin C, Bicarbonate
2) By Up Regulated Protein: Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), Interleukin-18 (IL-18)
3) By Other Biomarker Types: Proximal Tubule Injury Biomarkers, Acute Kidney Injury Biomarkers, Chronic Kidney Disease Biomarkers
Pre-Book The Renal Biomarkers Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Renal Biomarkers Market?
The renal biomarkers market is witnessing a surge in popularity due to the advent of technological advancements. With a determined focus on the development of innovative technologies, the major players in this sector are striving to maintain their market standing. For instance, Nipro Medical Corporation, a medical equipment production firm based in the US, introduced SURDIAL DX in March 2022. This state-of-the-art hemodialysis system features advanced technology designed to enhance patient safety, comfort, and operational efficiency. Novel elements such as automated processes, ergonomic design, and a dedication to improving the overall dialysis treatment experience are integrated into its design.
Who Are the Key Players in the Renal Biomarkers Market?
Major companies operating in the renal biomarkers market include:
• Abbott Laboratories
• BioPorto Diagnostics A/S
• Roche Holding AG
• Thermo Fisher Scientific
• bioMérieux SA
• Randox Laboratories
• Siemens Healthineers
• Beckman Coulter Inc.
• Astute Medical Inc.
• Nexelis Company
• Sphingotec GmbH
• Bio-Rad Laboratories India Pvt. Ltd.
• Enzo Biochem Inc.
• PerkinElmer Inc.
• Novartis AG
• Alere Inc.
• AstraZeneca plc
• Bio-Techne Corp.
• DiaSorin S.p.A.
• EKF Diagnostics Holdings plc
• Fujirebio Diagnostics Inc.
• Gold Standard Diagnostics Corp.
• Merck KGaA
• Myriad RBM Inc.
• Ortho Clinical Diagnostics Holdings plc
• Quidel Corporation
• R&D Systems Inc.
• Roche Diagnostics International Ltd .
• Sekisui Chemical Co. Ltd.
• Sysmex Corporation
• Tosoh Bioscience Inc.
What are the Regional Insights into the Renal Biomarkers Market?
North America was the largest region in the renal biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The regions covered in the renal biomarkers market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
